Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DanCann Pharma AS's enterprise value is $0.01 Mil.
DanCann Pharma AS's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $-1.05 Mil. Therefore, DanCann Pharma AS's EV-to-EBITDA for today is -0.01.
The historical rank and industry rank for DanCann Pharma AS's EV-to-EBITDA or its related term are showing as below:
DCPXF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.88 Med: -1.17 Max: -0.01
Current: -0.01
During the past 7 years, the highest EV-to-EBITDA of DanCann Pharma AS was -0.01. The lowest was -12.88. And the median was -1.17.
DCPXF's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 12.96
vs DCPXF: -0.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
DanCann Pharma AS (GREY:DCPXF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DanCann Pharma AS's PE Ratio (TTM) for today is calculated as:
DanCann Pharma AS's share price for today is $10.00.
DanCann Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.395.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for DanCann Pharma AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DanCann Pharma AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DanCann Pharma AS EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DanCann Pharma AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DanCann Pharma AS's EV-to-EBITDA falls into.
DanCann Pharma AS's current Enterprise Value is $0.01 Mil.
DanCann Pharma AS's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DanCann Pharma AS (DCPXF) has a EV-to-EBITDA of -0.01 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DanCann Pharma AS.
Is DanCann Pharma AS's EV-to-EBITDA too high?
DanCann Pharma AS's current EV-to-EBITDA is -0.01. Overall, DanCann Pharma AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's EV-to-EBITDA compare to ZTS and UTHR?
DanCann Pharma AS's EV-to-EBITDA of -0.01 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBITDA is 12.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DanCann Pharma AS. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DanCann Pharma AS's current EV-to-EBITDA is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (DCPXF) has a current EV-to-EBITDA of -0.01. The stock's GF Value™ is $37.14, compared to a current price of $10.00 — trading 73.1% below its estimated fair value. The current EV-to-EBITDA is -0.01. DanCann Pharma AS's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For DanCann Pharma AS (DCPXF), the current EV-to-EBITDA is -0.01 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DanCann Pharma AS (DCPXF) Overvalued in 2026?
Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued.
The current stock price of $10.00 is trading 73.1% below its estimated GF Value™ of $37.14.
Key valuation signals for DCPXF:
EV-to-EBITDA: -0.01
GF Value™: $37.14 vs. price of $10.00 (73.1% below fair value)
No single metric tells the full story. See the DCPXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
20GF Score
Get the complete analysis for DCPXF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCPXF has been successfully added to your 
